vTv Therapeutics (VTVT) Enterprise Value: 2014-2025
Historic Enterprise Value for vTv Therapeutics (VTVT) over the last 12 years, with Sep 2025 value amounting to -$23.9 million.
- vTv Therapeutics' Enterprise Value fell 527.94% to -$23.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$117.8 million, marking a year-over-year decrease of 15.59%. This contributed to the annual value of $9.3 million for FY2024, which is 65.09% down from last year.
- Latest data reveals that vTv Therapeutics reported Enterprise Value of -$23.9 million as of Q3 2025, which was down 219.49% from $20.0 million recorded in Q2 2025.
- Over the past 5 years, vTv Therapeutics' Enterprise Value peaked at $281.6 million during Q1 2021, and registered a low of -$23.9 million during Q3 2025.
- Its 3-year average for Enterprise Value is $30.5 million, with a median of $23.7 million in 2024.
- Over the last 5 years, vTv Therapeutics' Enterprise Value had its largest YoY gain of 75.29% in 2025, and its largest YoY loss of 527.94% in 2025.
- Quarterly analysis of 5 years shows vTv Therapeutics' Enterprise Value stood at $101.0 million in 2021, then fell by 27.00% to $73.8 million in 2022, then plummeted by 63.82% to $26.7 million in 2023, then crashed by 65.09% to $9.3 million in 2024, then tumbled by 527.94% to -$23.9 million in 2025.
- Its Enterprise Value stands at -$23.9 million for Q3 2025, versus $20.0 million for Q2 2025 and $41.5 million for Q1 2025.